

Publications

→ Edited Volume

1. Special Issue, Clinical implications of targeting lipid metabolism and associated pathways for cancer therapy, *Frontiers in Oncology*, Forthcoming 2024.

→ Book chapters

2. Munir R, and **Zaidi N.** Regulation of Lipid Metabolism Under Stress and Its Role in Cancer. Invited chapter in: *Metabolism and Epigenetic Regulation: Implications in Cancer. Springer. 2022*
3. Ameer F, Munir R, and **Zaidi N.** Invited chapter in: *Lipid Metabolism in Encyclopedia of Cancer 3rd edition. 2019.*
4. **Zaidi N** and Kalbacher H. Cathepsin E, Invited chapter in: *The Handbook of Proteolytic Enzymes 3rd Edition. 2012.*

→ Journal articles

1. Munir, R. & **Zaidi, N.** (2023). The one with the rumor: COVID-19-related conversations on Pakistani Twitter. *Public Health*, 225, 277-284
2. Munir, R., Lisec, J., Swinnen, J. V., & **Zaidi, N.** (2022). Too complex to fail? Targeting fatty acid metabolism for cancer therapy. *Prog Lipid Res*, 85, 101143.
3. Shoaib, N., ... **N. Zaidi**, Population-level median cycle threshold (Ct) values for asymptomatic COVID-19 cases can predict the trajectory of future cases. *PLoS One*, 2023. 18(3): p. e0281899.
4. Noureen, N. and **N. Zaidi**, Association between human leukocyte antigen (HLA) and end-stage renal disease (ESRD): a meta-analysis. *PeerJ*, 2023. 11: p. e14792.
5. Munir, R., N. Noureen, M. Bashir, N. Shoaib, A. Ashraf, J. Lisec and **N. Zaidi** (2022). "Cancer Awareness Measure (CAM) and Cancer Awareness Measure MYthical Causes Scale (CAM-MY) scores in Pakistani population." *Sci Rep* 12(1): 8887.
6. Shoaib, N., N. Noureen, A. Faisal, M. Zaheer, M. Imran, A. Ahsan, R. Munir, and **N. Zaidi.** (2022) Factors Associated with Cycle Threshold Values (Ct-Values) of Sars-Cov2-Rrt-Pcr. *Mol Biol Rep* 1-6.
7. Shoaib, N., Noureen, N., Munir, R., Shah, F. A., Ishtiaq, N., Jamil, N., . . . **Zaidi, N.** (2021). COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. *PLoS One*, 16(8), e0255999. doi:10.1371/journal.pone.0255999.
8. Lisec J, Jaeger C, Rashid R, Munir R, **Zaidi N:** Cancer cell lipid class homeostasis is altered under nutrient-deprivation but stable under hypoxia. *BMC Cancer* 2019, 19(1):501.
9. Munir R, Lisec J, Swinnen JV, **Zaidi N:** Lipid metabolism in cancer cells under metabolic stress. *Br J Cancer* 2019, 120(12):1090-1098.
10. Munir R, Lisec J, Jaeger C, **Zaidi N.** Abundance, fatty acid composition and saturation index of neutral lipids in colorectal cancer cell lines. *Acta Biochim Pol.* 2021.
11. Shoaib N, Bashir M, Munir R, Rashid R, **Zaidi N.** Expression of lipid transport-associated genes in lipid-deprived cancer cells. *Genes Cells.* 2021.
12. Riaz N, Munir R, Lisec J, **Zaidi N:** Revisiting the Association between Human Leukocyte Antigen and End-Stage Renal Disease. Accepted for publication in *PLOSone* August 2020.
13. Ameer F, Munir R, Usman H, Rashid R, Shahjahan M, Hasnain S, **Zaidi N:** Lipid-load in peripheral blood mononuclear cells: Impact of food-consumption, dietary-macronutrients, extracellular lipid availability and demographic factors. *Biochimie* 2017, 135:104-110.
14. Usman H, Ameer F, Munir R, Iqbal A, Zaid M, Hasnain S, Scandiuzzi L, **Zaidi N:** Leukemia cells display lower levels of intracellular cholesterol irrespective of the exogenous cholesterol availability. *Clin Chim Acta* 2016, 457:12-17.
15. Iqbal A, Zaid M, Munir R, Usman H, Kalbacher H, Scandiuzzi L, **Zaidi N:** Atypical plasma lipid profiles in leukemia. *Clin Chim Acta* 2016, 452:129-133.
16. Usman H, Rashid R, Ameer F, Iqbal A, Zaid M, Hasnain S, Kalbacher H, **Zaidi N:** Revisiting the dyslipidemia

associated with acute leukemia. *Clin Chim Acta* 2015, 444:43-49.

17. Rashid R, Ameer F, Kalbacher H, Scanduzzi L, **Zaidi N**: Aberrant de novo cholesterologenesis: Clinical significance and implications. *Clin Chim Acta* 2015.
18. Munir R, Usman H, Hasnain S, Smans K, Kalbacher H, **Zaidi N**: Atypical plasma lipid profile in cancer patients: cause or consequence? *Biochimie* 2014, 102:9-18.
19. Zaid M, Ameer F, Munir R, Rashid R, Farooq N, Hasnain S, **Zaidi N**: Anthropometric and metabolic indices in assessment of type and severity of dyslipidemia. *J Physiol Anthropol* 2017, 36:19.
20. Daniels VW, Smans K, Royaux I, Chypre M, Swinnen JV, **Zaidi N**: Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. *PLoS One* 2014, 9:e106913.
21. Ameer F, Scanduzzi L, Hasnain S, Kalbacher H, **Zaidi N**: De novo lipogenesis in health and disease. *Metabolism* 2014.
22. **Zaidi N**, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K: Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. *Prog Lipid Res* 2013, 52:585-589.
23. **Zaidi N**, Swinnen JV, Smans K: ATP-citrate lyase: a key player in cancer metabolism. *Cancer Res* 2012, 72:3709-3714.
24. **Zaidi N**, Royaux I, Swinnen JV, Smans K: ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms. *Mol Cancer Ther* 2012, 11:1925-1935.
25. Chypre M, **Zaidi N**, Smans K: ATP-citrate lyase: a mini-review. *Biochem Biophys Res Commun* 2012, 422:1-4.
26. **Zaidi N**, Maurer A, Nieke S, Kalbacher H: Cathepsin D: a cellular roadmap. *Biochem Biophys Res Commun* 2008, 376:5-9.
27. **Zaidi N**, Kalbacher H: Cathepsin E: a mini review. *Biochem Biophys Res Commun* 2008, 367:517-522.
28. **Zaidi N**, Hermann C, Herrmann T, Kalbacher H: Emerging functional roles of cathepsin E. *Biochem Biophys Res Commun* 2008, 377:327-330.
29. Waraich RS, **Zaidi N**, Moeschel K, Beck A, Weigert C, Voelter W, Kalbacher H, Lehmann R: Development and precise characterization of phospho-site-specific antibody of Ser(357) of IRS-1: elimination of cross reactivity with adjacent Ser(358). *Biochem Biophys Res Commun* 2008, 376:26-31.
30. Burster T, Reich M, **Zaidi N**, Voelter W, Boehm BO, Kalbacher H: Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells. *Biochem Biophys Res Commun* 2008, 377:1299-1303.
31. **Zaidi N**, Herrmann T, Voelter W, Kalbacher H: Recombinant cathepsin E has no proteolytic activity at neutral pH. *Biochem Biophys Res Commun* 2007, 360:51-55.
32. **Zaidi N**, Herrmann T, Baechle D, Schleicher S, Gogel J, Driessen C, Voelter W, Kalbacher H: A new approach for distinguishing cathepsin E and D activity in antigen-processing organelles. *FEBS J* 2007, 274:3138-3149.
33. **Zaidi N**, Burster T, Sommandas V, Herrmann T, Boehm BO, Driessen C, Voelter W, Kalbacher H: A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. *Biochem Biophys Res Commun* 2007, 364:243-249.

→ **Other Publications**

1. Cancer: Myths and Facts (Awareness Booklet), 2020. **Cancer Research Centre**.
2. **Zaidi, N.** (2015). Science and religion. The News. <http://tns.thenews.com.pk/science-religion/#.WaMFdtFLfIU>

→ **Abstracts published in Journals**

1. **Zaidi N**. Impact of low-lipid environment on de novo lipid synthesis pathways in cancer cells. *Journal for ImmunoTherapy of Cancer* 2015, 3(Suppl 2):P424
2. Abbas F, Sanaullah R, **Zaidi N**, Talati J, Siddiqui AA, Siddiqui K. A comparative assessment of the sensitivity of telomerase assay with other molecular markers for the diagnosis of human bladder cancer. *JPMA* (2002) 52: [Suppl12] ppS33.

3. Abbas F, Sanallah R, Zaidi N, Talati J, Siddiqui AA, Siddiqui K. A comparative assessment of the sensitivity of TRAP assay in diagnosis of human bladder cancer. **BJU International** 2004. Vol 94, Supplement.